CIBC Private Wealth Group LLC bought a new position in Crispr Therapeutics AG (NASDAQ:CRSP) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 4,390 shares of the company’s stock, valued at approximately $267,000.
Other institutional investors have also bought and sold shares of the company. NEXT Financial Group Inc lifted its position in Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after purchasing an additional 549 shares in the last quarter. Coastal Investment Advisors Inc. purchased a new position in Crispr Therapeutics during the third quarter valued at $26,000. Farmers & Merchants Trust Co of Chambersburg PA purchased a new position in Crispr Therapeutics during the fourth quarter valued at $26,000. Webster Bank N. A. purchased a new position in Crispr Therapeutics during the fourth quarter valued at $26,000. Finally, Clear Harbor Asset Management LLC purchased a new position in Crispr Therapeutics during the fourth quarter valued at $44,000. 50.01% of the stock is owned by institutional investors and hedge funds.
In other news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the transaction, the director now owns 7,500 shares in the company, valued at $412,500. The disclosure for this sale can be found here. Insiders sold 48,618 shares of company stock worth $3,230,760 over the last 90 days. Company insiders own 21.40% of the company’s stock.
Shares of Crispr Therapeutics stock opened at $52.32 on Friday. The stock’s 50-day simple moving average is $59.31 and its 200-day simple moving average is $52.83. Crispr Therapeutics AG has a 52 week low of $29.92 and a 52 week high of $74.00. The company has a market capitalization of $3.00 billion, a price-to-earnings ratio of -113.74 and a beta of 3.25. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06.
Several equities analysts recently weighed in on CRSP shares. Goldman Sachs Group lifted their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Roth Capital lifted their target price on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. BidaskClub downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 23rd. ValuEngine downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 3rd. Finally, Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $75.95.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: What are no-load funds?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.